Scarica l'app Stockscreener
15.62
3.55%
-0.575
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$16.20
Aprire:
$16.03
Volume 24 ore:
277.89K
Relative Volume:
0.47
Capitalizzazione di mercato:
$476.18M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.0458
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-5.76%
1M Prestazione:
-18.62%
6M Prestazione:
+0.42%
1 anno Prestazione:
+41.79%
Intervallo 1D:
$15.32
$16.10
Intervallo di 1 settimana:
$15.32
$16.80
Portata 52W:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.63 | 493.55M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.69 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics CEO to Present at Multiple Conferences - TipRanks
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Keros (NASDAQ:KROS) Capital Stability Draws Nasdaq Composite Discussion - Kalkine Media
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Will Keros Therapeutics Inc. stock keep outperforming rivalsQuarterly Market Review & Community Verified Trade Alerts - mfd.ru
Can Keros Therapeutics Inc. reach all time highs this yearJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - mfd.ru
Keros Therapeutics, Inc. (KROS) Stock Analysis: Spotlight on a 37.72% Potential Upside in Biotech - DirectorsTalk Interviews
Is Keros Therapeutics Inc. likely to announce a buybackMarket Performance Summary & Free Fast Entry Momentum Trade Alerts - mfd.ru
Why Keros Therapeutics Inc. stock could see breakout soon2025 Market Sentiment & Smart Allocation Stock Tips - mfd.ru
What analyst consensus says on Keros Therapeutics Inc. stockQuarterly Growth Report & Safe Entry Momentum Tips - mfd.ru
How much upside does Keros Therapeutics Inc. haveWeekly Trading Summary & Real-Time Buy Signal Alerts - mfd.ru
Keros Therapeutics: Key Catalysts and Financial Runway in Focus - AD HOC NEWS
Price-Driven Insight from (KROS) for Rule-Based Strategy - Stock Traders Daily
How Keros Therapeutics Inc. stock benefits from global expansion2025 Fundamental Recap & Reliable Entry Point Trade Alerts - mfd.ru
Y Intercept Hong Kong Ltd Lowers Holdings in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. $KROS Shares Sold by Federated Hermes Inc. - MarketBeat
Big Picture: What is SIDUs revenue forecastGap Up & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Risk Report: What is the next catalyst for Keros Therapeutics IncDividend Hike & High Accuracy Trade Alerts - baoquankhu1.vn
Tech Rally: Is CleanCore Solutions Incs ROE strong enough2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Aug Opening: Will HUB Cyber Security Ltd. Equity Warrant outperform during market ralliesJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - Nasdaq
Portfolio Shifts: Can NECB benefit from deglobalizationJuly 2025 Reactions & Community Driven Trade Alerts - baoquankhu1.vn
Market Wrap: What is the next catalyst for Keros Therapeutics IncAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is KROS' KER-065 the Next Breakthrough in DMD Space? - The Globe and Mail
(KROS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MRKR stock up nearly 114% in 3 months: Here's what you need to know - MSN
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Fund Flows: Does Keros Therapeutics Inc stock reflect fundamentalsWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
Is Keros Therapeutics Inc. backed by strong institutional buyingQuarterly Trade Summary & AI Driven Price Predictions - mfd.ru
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Nasdaq
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring a Promising 20.76% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - sharewise.com
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - sharewise.com
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
(KROS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Downgrade Watch: What’s the RSI of Keros Therapeutics Inc. stock2025 Performance Recap & Long-Term Safe Investment Plans - baoquankhu1.vn
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lerner Lorena Raquel | Chief Science Officer |
Feb 18 '26 |
Sale |
16.35 |
3,873 |
63,324 |
31,127 |
| Cho Esther | SVP, General Counsel |
Feb 18 '26 |
Sale |
16.35 |
4,745 |
77,581 |
39,755 |
| Regnante Keith | CHIEF FINANCIAL OFFICER |
Feb 18 '26 |
Sale |
16.35 |
4,739 |
77,483 |
39,261 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
4,787,331 |
84,975,125 |
0 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
5,389,264 |
95,659,436 |
0 |
0.88%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):